Skip to main content
EuroIntervention logoLink to EuroIntervention
. 2022 Mar 18;17(16):1310–1312. doi: 10.4244/EIJ-D-21-00595

Procedural and early outcomes of transcatheter edge-to-edge mitral valve repair in very elderly patients

Byomesh Tripathi 1, Tauseef Akhtar 2, Saket Girotra 3, Charanjit S Rihal 4, Sidakpal Panaich 5,*
PMCID: PMC9743246  PMID: 34483089

Introduction

Mitral regurgitation (MR) is a common valvular abnormality with an estimated prevalence of 2.1% for a moderate to severe degree of MR in population-based studies1. If untreated, MR leads to significant morbidity and mortality resulting from left ventricular dilatation and congestive heart failure (CHF)2. Transcatheter mitral valve repair using the MitraClip (Abbott Vascular) has revolutionised the treatment of patients with symptomatic severe primary MR who are at a prohibitive risk for surgery, and for those with symptomatic moderate to severe secondary MR refractory to guideline-directed medical therapy3,4. Given the association of ageing with MR, as well as concern for peri-operative mortality and morbidity with open-heart surgery, a rising proportion of elderly patients are undergoing the MitraClip procedure. However, there are limited data regarding procedural outcomes following the MitraClip procedure in elderly patients, especially nonagenarians. The objective of this study was to address this knowledge gap using data from a large national database.

Methods

The National Readmissions Database (NRD; 2015-2018) was used to identify patients with MR who underwent the MitraClip procedure using the International Classification of Diseases (ICD) procedure code ICD-10: 02UG3JZ. Similarly, post-procedural complications were identified using appropriate ICD-10 codes and included: complete heart block, need for permanent pacemaker, myocardial infarction, cardiogenic shock, cardiac arrest, pericardial complications, device related complications, stroke or transient ischaemic attack, acute kidney injury requiring haemodialysis, major bleeding, vascular complications, or conversion to mitral valve surgery. The study population was categorised into three comparison groups based on age (<80 years, 80-89 years, and ≥90 years). Outcomes assessed in our study included in-hospital mortality, 30-day readmission, CHF-related readmissions, and post-procedure complications. Hospitals were categorised into low-, intermediate- and high-volume centres according to their annual volume for MitraClip implantations (<5, 5-14 and ≥15, respectively). Hospital volume was identified using “Hosp_NRD” variable provided by the NRD. Our study was deemed exempt from institutional review as the NRD is a publicly available, de-identified database. SAS 9.4 (SAS Institute Inc.) was used for statistical analyses. The chi-square test was used to compare the differences between categorical variables. A hierarchical, multivariable, logistic regression model was performed to assess the effect of age on study outcomes. P-values of <0.05 were considered significant.

Results

We identified a total of 19,284 patients, of whom 8,905 were <80 years of age, 8,708 were 80-89 years old (octogenarian) and 1,671 were ≥90 years old (nonagenarian). The nonagenarian cohort included a greater proportion of females, as compared to the octogenarian and <80 year-old cohorts. The nonagenarian cohort had a higher prevalence of patients in the highest median household income category, with hypertension, CHF, nutritional anaemia, pulmonary hypertension, chronic kidney disease, non-elective admissions, and patients discharged to a skilled nursing facility. Patients in the <80 year-old cohort had a higher prevalence of diabetes mellitus, obesity, tobacco abuse, peripheral arterial disease, chronic obstructive pulmonary disease and liver disease, while atrial fibrillation/flutter was more prevalent in octogenarians (Table 1).

Table 1. Baseline characteristics and post-procedural outcomes after MitraClip implantation.

Age group (years old) <80 80-89 ≥90 p-value
Index admission 8,905 8,708 1,671
Baseline characteristics
Gender Male 55.9 51.3 48.8 <0.001
Female 44.1 48.7 51.2
Primary payer Medicare/Medicaid 82.7 95.6 96.4 <0.001
Others 17.4 4.4 3.6
Median household income category for patient's ZIP code 1. 0-25th percentile 26.2 18.6 15.4 <0.001
2. 26-50th percentile 26.7 25.0 22.1
3. 51-75th percentile 25.4 28.1 28.1
4. 76-100th percentile 21.7 28.3 34.5
Comorbidities (%) Hypertension 73.8 80.7 82.8 <0.001
Diabetes mellitus 33.9 21.4 15.3 <0.001
Obesity 15.4 5.9 2.3 <0.001
Smoker 41.7 33.3 28.5 <0.001
Congestive heart failure 80.3 80.6 81.5 NS
Atrial fibrillation/flutter 56.2 68.0 66.8 <0.001
Peripheral arterial disease 8.5 7.8 6.1 0.003
Prior MI 19.9 13.4 12.0 <0.001
Prior PCI 4.3 4.4 3.2 NS
Prior CABG 26.1 19.9 12.4 <0.001
Prior stroke 11.3 12.3 10.1 0.014
Prior pacemaker or ICD 24.0 21.8 19.4 <0.001
Anaemia 4.1 4.5 5.3 NS
Coagulopathy 2.7 1.7 1.5 <0.001
Prior VTE 6.7 5.5 3.8 <0.001
Chronic obstructive pulmonary disease 29.0 21.3 14.0 <0.001
Pulmonary hypertension 31.1 32.2 35.2 0.004
Chronic kidney disease 39.7 38.6 41.8 0.033
Liver diseases 2.3 0.8 0.8 <0.001
Hospital bedsize (number of beds) Small 4.0 4.8 3.5 0.027
Medium 21.4 21.3 23.2
Large 74.5 74.0 73.4
Teaching status§ Non-teaching 9.8 9.8 10.1 NS
Teaching 90.2 90.2 89.9
Admission type Non-elective 27.9 23.0 29.6 <0.001
Elective 72.1 77.0 70.4
Admission day Weekdays 95.5 96.3 94.5 <0.001
Weekend 4.5 3.7 5.5
Procedural outcomes
In-hospital mortality % 2.6 2.1 2.7 NS
Adjusted OR (95% CI)* Reference group</p> 0.80 (0.59-1.08) 0.97 (0.62-1.53) NS
30-day readmissions % 14.6 14.8 17.4 0.013
Adjusted OR (95% CI)* Reference group</p> 1.06 (0.94-1.20) 1.21 (1.00-1.47) NS
CHF-related readmissions % 11.3 14.1 11.5 NS
Adjusted OR (95% CI)* Reference group</p> 1.41 (0.97-2.05) 1.03 (0.57-1.87) NS
Procedural complications % 16.7 14.3 15.1 <0.001
Adjusted OR (95% CI)* Reference group</p> 0.80 (0.62-1.05) 0.79 (0.51-1.23) NS
Represents a quartile classification of the estimated median household income of residents in the patients ZIP Code, derived from ZIP Code-demographic data obtained from Claritas. The quartiles are identified by values of 1 to 4, indicating the poorest to wealthiest populations. Because these estimates are updated annually, the value ranges vary by year. https://www.hcup-us.ahrq.gov/db/vars/zipinc_qrtl/nrdnote.jsp. The bedsize cut-off points divided into small, medium, and large have been set so that approximately one-third of the hospitals in a given region, location, and teaching status combination would fall within each bedsize category. https://www.hcup-us.ahrq.gov/db/vars/hosp_bedsize/nrdnote.jsp. § A hospital is considered to be a teaching hospital if it has an AMA-approved residency program, is a member of the Council of Teaching Hospitals (COTH) or has a ratio of full-time equivalent interns and residents to beds of 0.25 or higher. https://www.hcup-us.ahrq.gov/db/vars/hosp_ur_teach/nrdnote.jsp. *All multivariable models are adjusted for gender, insurance status, median quartile income, hypertension, DM, obesity, smoking, CHF, AFIB, PAD, prior history of MI, prior history of PCI, prior history of CABG, prior history of stroke, presence of pacemaker or ICD, anaemia, coagulopathy, prior history of VTE, COPD, CKD, liver disease, hospital bed size, teaching status, elective versus urgent admission, and weekday vs weekend admission. CHF readmissions are provided as percentage of total all cause readmissions. 95% CI = 95% confidence interval; CABG: coronary artery bypass grafting; CHF: congestive heart failure; ICD: intracardiac defibrillator; MI: myocardial infarction; PCI: percutaneous coronary intervention; NS: not significant; OR: odds ratio; VTE: venous thromboembolism

Compared to patients <80 years of age, we noted no difference in in-hospital mortality or CHF-related 30-day readmissions among nonagenarians and octogenarians on univariate or multivariable models. On univariate comparison, nonagenarians appear to have had a high all-cause 30-day readmission rate. However, this difference was not seen with multivariate analysis. Similarly, post-procedural complications did not differ among comparative cohorts with multivariate analysis (Table 1). Increased institutional experience (>5 MitraClip/year) was associated with improved survival, fewer 30-day and CHF-related readmissions and a reduction in procedural complications in elderly patients (≥80 years). In patients <80 years of age, increased institutional experience was associated with improved survival and fewer procedural complications, without any statistically significant effect on readmissions (Supplementary Table 1).

Discussion

Our findings suggest that the safety and procedural outcomes of MitraClip implantation in elderly cohorts are comparable to those in younger patients. Additionally, the mortality among elderly patients who underwent the MitraClip procedure in our study was considerably lower (2.1 % in octogenarians and 2.7% in nonagenarians), compared to mitral valve surgery in this elderly patient population, which has been reported to be as high as 14% in previous studies5. Better outcomes in the elderly cohort could be the result of better patient selection, improvement in procedural technique, and greater operator experience. The noted higher socioeconomic profile of elderly patients in our study may also be a contributing factor to better outcomes. Additionally, the better outcomes associated with centres with higher annual volumes suggests that, in addition to careful patient selection, centres with high institutional experience are pivotal in improving outcomes among very elderly patients.

Limitations

Our study has a few limitations, including the observational nature of the dataset, the lack of imaging data and the unavailability of data related to the mechanism of MR. Also, due to the limitation of the database, we could not evaluate the impact of operator volume on outcomes.

Conclusions

Many elderly patients, including nonagenarians, enjoy a good quality of life and deserve the opportunity to maintain this quality of life. Our results demonstrate that, in well-selected patients, advanced age alone should not be a limiting factor for edge-to-edge repair with the MitraClip.

Supplementary data

Supplementary Table 1

Outcomes of MitraClip implantation among very elderly patients based on annual hospital volume of the centres.

Acknowledgments

Conflict of interest statement

The authors have no conflicts of interest to declare.

Contributor Information

Byomesh Tripathi, Division of Cardiology, University of Arizona College of Medicine, Phoenix, AZ, USA.

Tauseef Akhtar, Division of Cardiology, Johns Hopkins Hospital, Baltimore, MD, USA.

Saket Girotra, Division of Cardiovascular Medicine, University of Iowa, Iowa City, IA, USA.

Charanjit S. Rihal, Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.

Sidakpal Panaich, Division of Cardiovascular Medicine, University of Iowa, Iowa City, IA, USA.

References

  1. Jones EC, Devereux RB, Roman MJ, Liu JE, Fishman D, Lee ET, Welty TK, Fabsitz RR, Howard BV. Prevalence and correlates of mitral regurgitation in a population-based sample (the Strong Heart Study). Am J Cardiol. 2001;87:298–304. doi: 10.1016/s0002-9149(00)01362-x. [DOI] [PubMed] [Google Scholar]
  2. Nishimura RA, Vahanian A, Eleid MF, Mack MJ. Mitral valve disease- -current management and future challenges. Lancet. 2016;387:1324–34. doi: 10.1016/S0140-6736(16)00558-4. [DOI] [PubMed] [Google Scholar]
  3. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Fleisher LA, Jneid H, Mack MJ, McLeod CJ, O’Gara PT, Rigolin VH, Sundt TM, Thompson A. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;70:252–89. doi: 10.1016/j.jacc.2017.03.011. [DOI] [PubMed] [Google Scholar]
  4. O’Connor CM. Guideline-Directed Medical Therapy Clinics: A Call to Action for the Heart Failure Team. JACC Heart Failure. 2019;7:442–3. doi: 10.1016/j.jchf.2019.04.001. [DOI] [PubMed] [Google Scholar]
  5. Ailawadi G, Swenson BR, Girotti ME, Gazoni LM, Peeler BB, Kern JA, Fedoruk LM, Kron IL. Is mitral valve repair superior to replacement in elderly patients? Ann Thorac Surg. 2008;86:77–85. doi: 10.1016/j.athoracsur.2008.03.020. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Table 1

Outcomes of MitraClip implantation among very elderly patients based on annual hospital volume of the centres.


Articles from EuroIntervention are provided here courtesy of Europa Group

RESOURCES